A Multicenter, Randomized, Double-blind, Controlled Phase III Clinical Trial on the Efficacy, Safety, and Immunogenicity of the Bivalent Enterovirus Inactivated Vaccine (Vero Cell) in Children Aged 6 to 71 Months.
Latest Information Update: 03 Jan 2025
Price :
$35 *
At a glance
- Drugs Bivalent-enterovirus-inactivated-vaccine-Sinovac-Biotech (Primary)
- Indications Enterovirus A infections
- Focus Pharmacodynamics; Registrational; Therapeutic Use
- Sponsors Sinovac Biotech
- 01 Jan 2025 Status changed from not yet recruiting to recruiting.
- 23 Dec 2024 New trial record